Scientific Advisory Board

Allan was the inaugural Institute Director of the GSK Vaccines Institute for Global from 2007 until 2019, working on vaccines for enteric diseases and Group A streptococcus.

Prior to this, Allan worked on the development of malaria vaccines, malaria epidemiology and laboratory-based research in malaria antigen identification. Allan held previous appointments as co-branch chief of the Malaria Vaccine Development Branch, NIH and at the Queensland Institute of Medical Research in Brisbane, Australia.

Allan now is active on the advisory boards of multiple international vaccine development and funding programs, especially for diseases of Low- and Middle-Income Countries.

Allen Cheng is an infectious diseases physician, Director of Infection Prevention and Healthcare Epidemiology at Alfred Health and Professor of Infectious Diseases Epidemiology at Monash University. He has academic interests in influenza surveillance and vaccination and previously held the positions of Chair of the Advisory Committee for Vaccines and co-Chair of the Australian Technical Group on Immunisation (ATAGI).

Michel De Wilde holds a PhD in Biochemistry and has a long and successful career in Vaccine Research and Development. He currently consults for the vaccine community and serves on a number of Advisory Boards.

From 2001 till June 2013, Michel De Wilde was Senior Vice President, Research & Development, at Sanofi Pasteur where he drove the development and licensure of a number of products.

From 1978 till 2000, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) where he held positions of increasing responsibility. He played a key role in the development of several new vaccines, most notably the recombinant Hepatitis B vaccine, as well as GSK’s Malaria vaccine.

Dr. Cheryl Keech works to develop solutions for vaccine-preventable diseases by focusing on strategic product development: designing innovative, fit-for-purpose clinical trials and supporting assay development, national/global regulatory interactions, pharmacovigilance, and health technology assessments.  She has led clinical development programs for multiple vaccine platforms across multiple organizations (Pharma, NGO, Biotech, CRO), spanning all major markets, global regions, World Bank economies and development phases (pre- and post-licensure).  She believes that through partnering, strong value propositions can be developed; with the goal of obtaining an optimal benefit-to-risk profile for a potential vaccine. She has a passion for ensuring vaccines provide global health equity.

Jerome Kim, M.D., is an international expert on the evaluation and development of vaccines and is the Director General of the International Vaccine Institute, whose mission is to discover, develop and deliver safe, effective and affordable vaccines for Global Health. Dr. Kim is also an Distinguished Visiting Professor, College of Natural Sciences, Seoul National University. He has authored over 300 publications. He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology, and received his M.D. from Yale University School of Medicine.

Wayne C. Koff, Ph.D, is the founding President and CEO of the Human Vaccines Project (HVP), a non-profit global research consortium with the mission to decode the human immune system to accelerate development of vaccines and therapies for infectious and non-communicable diseases. In addition, he was an adjunct professor of epidemiology at the Harvard T.H. Chan School of Public Health (HSPH) between 2020 and 2024, where he led the HSPH-HVP Human Immunomics Initiative, focusing on deciphering the principles of effective immunity in aging populations.  In 2019, he was honored by Foreign Policy, along with Barack and Michelle Obama and Angela Merkel as one of on the thinkers and doers who had a profound impact on the planet in the last 12 months. Between 1996-2016, Koff led the research and development program for the International AIDS Vaccine Initiative.

Terry Nolan is Redmond Barry Distinguished Professor Emeritus at the University of Melbourne, and the former head of the Vaccine and Immunisation Research Group (or VIRGo) at the Peter Doherty Institute for Infection and Immunity and the Murdoch Children’s Research Institute. He was the Foundation Head of the Melbourne University School of Population and Global Health between 2001 and 2019.

Prof. Nolan is a pediatrician and clinical epidemiologist, graduated in medicine and in medical science from the University of Western Australia, trained in paediatrics at the Royal Children’s Hospital in Melbourne and at the Montréal Children’s Hospital, and received a PhD in epidemiology and biostatistics from McGill University in Montréal.

Shiranee Sriskandan is Professor of Infectious Diseases and a Clinical Infectious Diseases consultant. She leads the Gram Positive Pathogenesis research group at Imperial College; she is also the Co-Director of the Centre for Bacterial Resistence Biology.

Her research addresses the mechanisms by which Streptococcus pyogenes causes extreme clinical phenotypes in individuals and populations, examining pathogen molecular microbiology, pathogen transmission, and host immune response, working in collaboration with colleagues in Public Health England. She has a strong interest in streptococcal vaccines and changes in S. pyogenes that might influence vaccine targets.

Mark Sullivan is a development scientist and clinical researcher with a depth of experience in phase I, II and III registrational clinical trials, and has held senior roles in the development of 3 globally approved molecules. Mark was project leader for the registration of moxidectin through the US FDA in 2018 for the treatment of onchocerciasis. He has experience of product development in 6 continents and has also has led vector and DNA-based vaccine development. Mark was 2019 VIC Australian of the Year, EY Australian Entrepreneur 2019 and ATSE Clunies Ross Award winner in 2020. He is an Honorary Professor at UNSW.

Professor Alex Brown (BMed, MPH, PhD, FRACP (hon.), FCSANZ,  FAAHMS) is the Professor of Indigenous Genomics at Telethon Kids Institute and the National Centre for Indigenous Genomics at ANU. Alex is an internationally leading Aboriginal clinician/researcher who has worked his entire career in Aboriginal health in the provision of public health services, chronic disease care, health care policy and research. He has established four highly regarded research groups over the last 20 years, and much of his work has been at the difficult interface of geographical isolation, complex cultural context, severe socioeconomic disadvantage, inequitable access to and receipt of care and profound health disparities. His transdisciplinary program of research focuses on documenting the burden and contributors to health inequality in Indigenous Australians, with a primary focus on cardiovascular disease (CVD), diabetes and cancer, and exploring the role of genomics in reducing health inequalities.

Dr. Norman W. Baylor is currently the Chair of the Board of Directors of Biologics Consulting Group, Inc., a scientific, regulatory, and clinical consulting firm that provides national and international regulatory and product development strategy and advice. Dr. Baylor was formerly the Director of the Office of Vaccines Research and Review (OVRR) at the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research. He has evaluated and/or facilitated the development and licensure of numerous vaccines and related products during his 20-year career at FDA. Dr. Baylor served as FDA’s liaison to CDC’s Advisory Committee on Immunization Practices, the US Department of Health and Human Services National Vaccine Advisory Committee, the Advisory Commission on Childhood Vaccines, and a member of the NIH NIAID Council. Dr. Baylor has served as an expert advisor to the World Health Organization on several global vaccine initiatives. He is a member of the Board of Trustees at the Sabin Vaccine Institute in Washington, DC. He is also the Editor-in-Chief of the Journal of the International Alliance for Biological Standardization (IABS).